BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32043900)

  • 1. Targeting effector pathways in RAC1
    Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
    Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
    Araiza-Olivera D; Feng Y; Semenova G; Prudnikova TY; Rhodes J; Chernoff J
    Oncogene; 2018 Feb; 37(7):944-952. PubMed ID: 29059171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAC1
    Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
    Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC1 as a Therapeutic Target in Malignant Melanoma.
    Cannon AC; Uribe-Alvarez C; Chernoff J
    Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
    Foth M; Parkman G; Battistone B; McMahon M
    Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
    Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
    Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
    Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
    Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAC1 and melanoma.
    Halaban R
    Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
    Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis.
    Yu-Wai-Man C; Spencer-Dene B; Lee RMH; Hutchings K; Lisabeth EM; Treisman R; Bailly M; Larsen SD; Neubig RR; Khaw PT
    Sci Rep; 2017 Mar; 7(1):518. PubMed ID: 28364121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
    Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
    Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAC1P29S is a spontaneously activating cancer-associated GTPase.
    Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAC1 P29S regulates PD-L1 expression in melanoma.
    Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
    Haak AJ; Appleton KM; Lisabeth EM; Misek SA; Ji Y; Wade SM; Bell JL; Rockwell CE; Airik M; Krook MA; Larsen SD; Verhaegen M; Lawlor ER; Neubig RR
    Mol Cancer Ther; 2017 Jan; 16(1):193-204. PubMed ID: 27837031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
    Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
    Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRAS
    Banik I; Cheng PF; Dooley CM; Travnickova J; Merteroglu M; Dummer R; Patton EE; Busch-Nentwich EM; Levesque MP
    Pigment Cell Melanoma Res; 2021 Mar; 34(2):150-162. PubMed ID: 32910840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.
    Johnson LA; Rodansky ES; Haak AJ; Larsen SD; Neubig RR; Higgins PD
    Inflamm Bowel Dis; 2014 Jan; 20(1):154-65. PubMed ID: 24280883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
    Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
    J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation and outcome of RAC1 mutated melanoma.
    Lodde GC; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Sucker A; Placke JM; Zaremba A; Albrecht LJ; Kowall B; Galetzka W; Becker JC; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Schadendorf D; Ugurel S; Griewank K
    Eur J Cancer; 2023 Apr; 183():1-10. PubMed ID: 36773463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.